


Artificial-intelligence-augmented clinical medicine

Klaus-Peter Adlassnig

Section on Medical Expert and Knowledge-Based Systems
Medical University of Vienna
Spitalgasse 23
A-1090 Vienna, Austria



4th International Symposium on Health Informatics and Bioinformatics, Ankara,
Turkey, 17 April 2009

Artificial intelligence (1)

- *Definition 1:* AI is a field of science and engineering concerned with the computational understanding of what is commonly called intelligent behavior, and with the creation of artifacts that exhibit such behavior.

from: Shapiro, S.C. (1992) Artificial Intelligence. In Shapiro, S.C. (ed.) *Encyclopedia of Artificial Intelligence*, 2nd ed., vol. 1, Wiley, New York, 54–57.

- *Definition 2:* AI is the science of artificial simulation of human thought processes with computers.

from: Feigenbaum, E.A. & Feldman, J. (eds.) (1995) *Computers & Thought*. AAAI Press, Menlo Park, back cover.


Artificial intelligence—applicable to clinical medicine

- It is the **decomposition** of an **entire clinical thought process** and its separate artificial simulation—also of simple instances of “clinical thought”—that make the task of **AI in clinical medicine** manageable.
- A functionally-driven science of AI that **extends clinicians through computer systems** step by step can immediately be established.




artificial-intelligence-augmented clinical medicine

Computational intelligence in medical research



Computational intelligence in patient care




Computers in clinical medicine

Steps of natural progression

- step 1: patient administration
 - ADT and billing
 - step 2: medical data
 - electronic health record
 - step 3: medical data retrieval and analysis
 - research databases, studies, quality management
 - **step 4: knowledge-based systems for clinical decision support**
 - safety net, patient-centered quality assurance
 - ... for the individual patient
 - ... and the physician
 - ... and the medical institution
-

Medical information and knowledge-based systems



Clinical decision support

diagnosis • clinical alerts, reminders, calculations • data interpretation, (tele)monitoring • single or differential diagnosis – further or redundant diagnostic investigations – all pathological signs accounted for • consensus-criteria-based diagnosis – definitions – classification criteria	therapy • drug alerts, reminders, calculations – indication, contraindications, redundant medications, substitutions – drug allergies, interactions, dosage calculations, consequent orders • management of antibiotics therapy • (open-loop) control systems
prognosis • illness severity scores, prediction rules • trend detection and visualization	patient management • administrative reminders • computerized clinical guidelines, protocols • community- and hospital-acquired infections, cross infections • high-level patient and hospital analytics

Hepaxpert/Interpretation

Knowledge-based interpretation of hepatitis A, B, and C serology

Input of test results

Interpretation

FAQs

Scientific development

Scientific publications

Feedback

English version

Deutsche Version

Interpretation

user: mxt [logout](#)

Hepatitis A serology

anti-HAV	IgM anti-HAV	HAV-RNA
positive	not tested	not tested

Antibodies to the hepatitis virus A may occur in three different situations: (a) in the case of a recent hepatitis A virus infection (acute icteric or anicteric hepatitis A, subclinical disease, or stage of convalescence from hepatitis A), (b) in the case of immunity after an earlier hepatitis A virus infection, or (c) after active vaccination or in the case of passively acquired immunity through injection of gamma globulin.

Hepatitis B serology

HBsAg	anti-HBs	anti-HBc	IgM anti-HBc
negative	not tested	not tested	negative
HBeAg	anti-HBe	anti-HBs titre	
not tested	not tested	2000 U/l	

This constellation of findings (positive anti-HBs antibodies, with negative IgM anti-HBc antibodies) indicates the presence of immunity to the hepatitis virus B. This immunity may either have been acquired naturally upon restitution following a hepatitis B virus infection or it may have been induced by active or passive immunization.

Vaccination Recommendation: If an indication for a hepatitis B vaccination exists, the primary course of immunization has been completed, the last partial vaccination was given at least 1 month previously, and the vaccinated person's immunity is unimpaired, then a hepatitis B vaccination (or a follow-up anti-HBs titre check) within 5 years, based on the titre examination date, is to be recommended at the measured anti-HBs titre value of 2000 U/l.

Hepatitis C serology

anti-HCV	HCV-RNA
positive	negative

The findings obtained give an indication of a formerly passed HCV infection or the remission of a present HCV infection. If on account of the clinical picture hepatitis C is suspected, follow-up tests are recommendable. Blood of such patients may be considered as infectious with regard to hepatitis C.

Important Notice

The attending physician alone is responsible for the patient's diagnosis and therapy. Therefore, contact a doctor at all times. Only the doctor will be able to align the Hepaxpert interpretation with the full clinical picture of the patient.

One of the rules to interpret clinically relevant findings (rule premises form equivalent classes)

RULE 103:

IF one of the following 100 combinations

HBsAg	anti-HBs	anti-HBc	IgM anti-HBc	HBeAg	anti-HBe
+	+	– ±	– ± •	+	– ± •
+	+	+	+	+	+

THEN

The simultaneous occurrence of HBe-antigen and anti-HBs antibodies is a rare event in the natural course of a hepatitis B virus infection. This constellation of findings may be attributed to one of the following causes: (a) circulating HBsAg-anti-HBs immune complexes, (b) hepatitis B virus infection coinciding with a hepatitis B vaccination or injection of HB-hyperimmune globulin, or (c) reinfection with a hepatitis virus B with a different HBsAg subtype. Blood and secretions (saliva, sperm, breast milk) of such patients are to be regarded as infectious.

PROTEINDIAGNOSTIK

CRP	61.5 ***	0.8-5.0	mg/l
-----	----------	---------	------

HORMONE

TSH	3.00	0.2-3.5	mU/l
-----	------	---------	------

INFEKTIONSSEROLOGIE

HIV-Antikörper	Negativ	Negativ
----------------	---------	---------

HEPATITIS-SEROLOGIE

Anti-HAV-IgM	Negativ	Negativ
Anti-HAV	Positiv *	Negativ
HBsAG	Negativ	
Anti-HBs	Negativ	
Anti-HBs (quant.)	1.42	U/l
Anti-HBc	Negativ	
Anti-HCV	Negativ	Negativ

Medizin. Kommentar/Interpretation:

HEPATITIS-SEROLOGIE:

Positive Gesamtkörper (Anti-HAV) bei negativen IgM-anti-HAV Antikörpern beweisen Immunität gegen das Hepatitis-A-Virus und schließen eine rezente Hepatitis A aus. Diese Immunität kann entweder durch eine frühere Infektion natürlich erworben oder aber durch aktive Impfung oder passive Immunisierung induziert sein.

Anti-HBs Titer: 1 Units/Liter

Eine bestehende oder frühere Hepatitis-B-Virusinfektion kann (mit Ausnahme des Inkubationsstadiums) ausgeschlossen werden. Es besteht keine Immunität gegen das Hepatitis-B-Virus. Das Blut kann hinsichtlich Hepatitis B als nicht infektiös angesehen werden. Impfempfehlung: Die Indikation zur Hepatitis-B-Impfung vorausgesetzt, soll in diesem Fall bei einem Ungeimpften die Grundimmunisierung (entsprechend dem Schema des jeweiligen Impfstoffes) durchgeführt und - zur Abschätzung der Immunantwort - 1-2 Monate nach der letzten Teilimpfung der Anti-HBs Titer bestimmt werden. Bei einem Geimpften mit abgeschlossener Grundimmunisierung soll unverzüglich eine Booster Injektion gegeben und - falls der Verdacht eines *low responders* besteht - eine Titerkontrolle 2 Monate nach dem Booster erhoben werden.

test results

interpretation

ORBIS Experte: Hepatitis serology diagnostics

ORBIS

Datei Bearbeiten Fenster Extra ?

10.11.2005 13:26:54 DEMO -05.03.29.4410

IM/ST1 FLEMING

Übersichten

Station

Funktionsbereich

OP-Bereich

Expertensystem

Hepaxpert III

Myrexpert

RheumExpert

geöffnete Akten

Bauer, Mathias

Diagnosen

Prozeduren

Kumulativbefund Labor

Krankengeschichte

Abrechnung

DRG Workplace

Fieberkurve

ICU-Scoring

Interne Leistungen

Zusatzinfos

Hepaxpert III

Hep. A

Hep. B

Hep. C

Anti-HAVA Negativ

IgM anti-HAV Positiv

HAV Grenzwertig

Anti-HBs Positiv

Anti-HBs Titr 50

HBsAg Positiv

Anti-HBc Negativ

IgM_anti_HB Negativ

HbeAg Positiv

Anti_HBe Nicht gemessen

Anti_HCV Positiv

HCV_RNA Grenzwertig

Ergebnisse

Hepatitis A

Der Befund enthält Widersprüche, da definitionsgemäß bei Vorliegen von IgM-anti-HAV-Antikörpern auch die Gesamtkörper Anti-HAV positiv sein müßten.

Rücksprache mit dem Laborleiter wird empfohlen. Zur Kontrolle des nicht eindeutig negativen oder positiven Befundes wird neuerliche Materialeinsendung empfohlen.

Hepatitis B

Das gleichzeitige Auftreten von HBe-Antigen und Anti-HBs-Antikörpern ist im natürlichen Verlauf einer Hepatitis-B-Virusinfektion ein seltenes Ereignis. Diese Befundkonstellation ist entweder auf (a) zirkulierende HBsAg-Anti-HBs-Immunkomplexe, (b) auf eine Koinzidenz einer Hepatitis-B-Virusinfektion mit einer Hepatitis-B-Impfung oder Injektion von HB-Hyperimmunglobulin oder (c) eine Reinfektion mit einem Hepatitis-B-Virus mit unterschiedlichem HBsAg-Subtypus zurückzuführen. Blut und Sekrete (Speichel, Sperma, Muttermilch) solcher Patienten sind als infektiös anzusehen.

Hepatitis C


Es besteht eine rezente oder chronisch persistierende oder eine früher abgelaufene Hepatitis-C-Virusinfektion. Die Bestimmung von HCV-RNA bringt zusätzliche Information. Das Blut solcher Personen ist hinsichtlich Hepatitis C als infektiös anzusehen.

Zur Kontrolle des nicht eindeutig negativen oder positiven Befundes wird neuerliche Materialeinsendung empfohlen.




Stammdaten
Anamnese
Status
Labor/Röntgen
Diagnosevorschlag


Status Gelenke



Detailansicht



Transparenz des Körpers



Status Wirbelsäule

Fingerbodenabstand cm

Schobersche Distanz cm

Menellsche Zeichen ☐ re ☐ li

Beckentiefstand ☐ re ☐ li

re: Beinlänge cm

li: Beinlänge cm

periphere Lähmung ☐ re ☐ li

OE ☐ re ☐ li

UE ☐ re ☐ li

MCP4 li.

- ☒ Druckschmerz
- ☒ Bewegungsschmerz
- ☐ periartikulärer Schmerz
- ☐ Schwellung, knöchern
- ☒ Schwellung, weich
- ☐ Schwellung, Erguß
- ☐ Rötung
- ☐ Bewegungseinschränkung

graphische Darstellung
Übersicht
Hände
Füße
Wirbelsäule



Stammdaten

Anamnese

Status

Labor/Röntgen

Diagnosevorschlag


Diagnosevorschlag

mögliche Diagnosen

- ☒ Verdacht auf entzündliche Gelenkerkrankung
 - ☒ Verdacht auf reaktive Arthritis
 - ☒ Verdacht auf Arthropathia psoriatica
 - ☒ Verdacht auf chronische Polyarthritis
 - ☒ Verdacht auf metabolische Gelenkerkrankung

ausgeschlossene Diagnosen

- ☐ Verdacht auf mechanische Ursache der Rückenbeschwerden
 - ☐ Verdacht einer malignen Erkrankung als Ursache der Rückenbeschwerden
 - ☐ Verdacht eines Traumas als Ursache der Rückenbeschwerden
 - ☐ Verdacht auf funktionelle oder degenerative Rückenbeschwerden
 - ☐ Verdacht auf Nervenwurzelkompression der Wirbelsäule
- ☐ Verdacht auf entzündliche Wirbelsäulenerkrankung
 - ☐ Verdacht auf bakterielle Spondylarthritis
 - ☐ Verdacht auf Spondylitis ancylosans
 - ☐ Verdacht auf Spondylarthropathia psoriatica
 - ☐ Verdacht auf Spondylarthritis bei Reiter-Syndrom
 - ☐ Verdacht auf Spondylarthritis bei Enteropathie (Morbus Crohn usw.)
 - ☐ Verdacht auf metabolische Wirbelsäulenerkrankung



data-to-symbol conversion

	Status der Gelenke															
	Schwellung						Rötung		Druck-Schmerz		Bew.-Schmerz		Bew.-Einschr.		periarth. Schmerz	
	knöchern		weich		Erguß		re	li	re	li	re	li	re	li	re	li
Temporom.	☐	☐	☐	☐	☐	☐	☐	☐	☐	☐	☐	☐	☐	☐	☐	☐
Akroniokl.	☐	☐	☐	☐	☐	☐	☐	☐	☐	☐	☐	☐	☐	☐	☐	☐
Sternoklav.	☐	☐	☐	☐	☐	☐	☐	☐	☐	☐	☐	☐	☐	☐	☐	☐
Schulter	☐	☐	☐	☐	☐	☐	☐	☐	☐	☐	☐	☐	☐	☐	☐	☒
Ellbogen	☐	☐	☐	☐	☐	☐	☐	☐	☐	☐	☐	☐	☐	☐	☐	☐
Hand	☐	☐	☐	☐	☐	☐	☐	☐	☒	☐	☒	☐	☐	☐	☐	☐
MCP 1	☐	☐	☐	☐	☐	☐	☐	☐	☐	☐	☐	☐	☐	☐	☐	☐
MCP 2	☐	☐	☐	☐	☐	☐	☐	☐	☐	☐	☐	☐	☐	☐	☐	☐
MCP 3	☐	☐	☐	☐	☐	☐	☐	☐	☐	☐	☐	☐	☐	☐	☐	☐
MCP 4	☐	☐	☐	☐	☐	☐	☐	☐	☐	☐	☐	☐	☐	☐	☐	☐
MCP 5	☐	☐	☐	☐	☐	☐	☐	☐	☐	☐	☐	☐	☐	☐	☐	☐
PIP 1	☐	☐	☐	☐	☐	☐	☐	☐	☐	☐	☐	☐	☐	☐	☐	☐
PIP 2	☐	☐	☐	☐	☐	☐	☐	☐	☐	☐	☐	☐	☐	☐	☐	☐
PIP 3	☐	☐	☐	☐	☐	☐	☐	☐	☐	☐	☐	☐	☐	☐	☐	☐
PIP 4	☐	☐	☐	☐	☐	☐	☐	☐	☐	☐	☐	☐	☐	☐	☐	☐
PIP 5	☐	☐	☐	☐	☐	☐	☐	☐	☐	☐	☐	☐	☐	☐	☐	☐
DIP 2	☐	☐	☐	☐	☐	☐	☐	☐	☐	☐	☐	☐	☐	☐	☐	☐
DIP 3	☐	☐	☐	☐	☐	☐	☐	☐	☐	☐	☐	☐	☐	☐	☐	☐
DIP 4	☐	☐	☐	☐	☐	☐	☐	☐	☐	☐	☐	☐	☐	☐	☐	☐
DIP 5	☒	☐	☐	☐	☐	☐	☐	☐	☒	☐	☐	☐	☐	☐	☐	☐
IP 1	☐	☐	☐	☐	☐	☐	☐	☐	☐	☐	☐	☐	☐	☐	☐	☐
IP 2	☐	☐	☐	☐	☐	☐	☐	☐	☐	☐	☐	☐	☐	☐	☐	☐
IP 3	☐	☐	☐	☐	☐	☐	☐	☐	☐	☐	☐	☐	☐	☐	☐	☐
IP 4	☐															

degenerative affection of one or more distal joints

at least 1 out of 18:
DIP r or DIP l or IP r or IP l and
per joint: (tenderness or pain on motion) and
osseous swelling


~~symbol level~~

[illegible]

Uncertainty in medicine

- **imprecision** (=fuzziness) of medical concepts
 - due to the unsharpness of boundaries of linguistic concepts; gradual transition from one concept to another
 - modeled by fuzzy sets
 - **uncertainty** of medical conclusions
 - due to the uncertainty of the occurrence and co-occurrence of imprecise medical concepts
 - modeled by SigmaCounts (unconditioned and conditioned frequencies of fuzzy sets)
 - **incompleteness** of medical data and medical theory
 - due to only partially known data and partially known explanations for medical phenomena
 - modeled by fuzzy intervals
-

Crisp sets vs. fuzzy sets




yes/no decision

$$U = [0, 120]$$

$$Y \subseteq U \text{ with } Y = \{(\chi_Y(x) / x) \mid x \in U\}$$

$$\chi_Y: U \rightarrow \{0, 1\}$$

$$\chi_Y(x) = \begin{cases} 0 & x > \text{threshold} \\ 1 & x \leq \text{threshold} \end{cases} \quad \forall x \in U$$



gradual transition


$$U = [0, 120]$$

$$Y \subseteq U \text{ with } Y = \{(\mu_Y(x) / x) \mid x \in U\}$$

$$\mu_Y: U \rightarrow [0, 1]$$


$$\mu_Y(x) = \begin{cases} \frac{1}{1 + (0.04 x)^2} & x > \text{threshold} \\ 1 & x \leq \text{threshold} \end{cases} \quad \forall x \in U$$

Degree of compatibility [= degree of membership]



glucose level in serum of 130 mg/dl

Calculation of fuzzy sets from sample data



Healthy persons:

$n = 151$

$\min = 8.2$

$\max = 23.8$


$\Phi_{0,05} = 11.6$

$\Phi_{0,95} = 21.24$

$$\mu_{\perp} = \pi(x; 8.2; 9.9; 11.6; 21.24; 22.52; 23.8)$$

(i) 90% confidence interval:
[10; 12.1]

(ii) 90% confidence interval:
[20.5; 22.9]



monitoring

pulsoximeter

PDMS & FuzzyKBWean

ventilator

intubated patient

HR	SpO2	EtCO2	Rsp_m	Vrate	I_E	TVex	pCO2a	pO2a	pHa	RMV	RSPcap	FiO2	PEEP	PIP	Delta	EtCO2corr
83.75	98.00	29.26	14.25	15.00	2.00	0.538				7.98	15.00	34.00	3.00	16.00	1.02	30.28

Time & Date

22:53 1999.01.22



Changes

proposed: 29 * 14,11

effective:

Confirm

Proposals:


Ventilation_3 Hyperventilation : PIP -2
Oxygenierung_1 Oxygenierung normal : FiO2 -5

Spec. Data-Set

19 _ _ _ : _ Data Set

Comment


Empty Table



HR
FiO2
PropFiO2
SpO2
EtCO2
EtCO2corr

HR
FiO2
PropFiO2
SpO2
EtCO2

410



PIP
PIP_Prop
PEEP
PEEP_Prop

PIP
PIP_Prop
PEEP
PEEP_Prop
VRate

3D

5:36:25

Knowledge base: BIPAP_fuzzy_2000

Rules (detailed) (17)

Rule Ventilation_1

☒ Confirm actions

Font size 10

if

and

then

- hasNotFiredRule
 - Oxygenierung_2
 - 20
- hasNotFiredRule
 - Extubation_1
 - 15
- isValid
 - EtCO2
 - 0
- hasNotFiredRule
 - Ventilation_1
 - 30
- in
 - mean
 - EtCO2
 - 1
 - 30
 - EtCO2_wean\normal
- in
 - EtCO2
 - EtCO2_wean\normal
- in
 - TVex
 - TVex\normal

Set output values

FiO2	PIP	PEEP	dPIP
[%]	[mbar]	[mbar]	
	-3		

Display message

Weaning :Ventilation im Normalbereich

Block / unblock groups and rules


- < no group >
- Meßfehler_1
- Meßfehler_2
- Ventilation_1
- Ventilation_2
- Ventilation_3
- Oxygenierung_1
- Oxygenierung_2
- Oxygenierung_3
- Extubation_1
- inv_PIP
- Anstieg_EtCO2

☒ Block☐ = minute(s)☐ = until unblocked☒ Unblock

Don't change

Set mode of operation < no change >

Fuzzy control



increased
disposition by
low immunity

exposure to
pathogens

ESBL - extended spectrum beta-lactamase

VRE - vancomycin-resistant enterococcus


MRSA - methicillin-resistant *Staphylococcus aureus*

MDR-TB - multidrug-resistant tuberculosis



entry sites





INFECTION SITE: Symptomatic urinary tract infection

CODE: UTI-SUTI

DEFINITION: A symptomatic urinary tract infection must meet at least one of the following criteria:

Criterion 1: Patient has at least *one* of the following signs or symptoms with no other recognized cause: fever ($>38^{\circ}\text{C}$), urgency, frequency, dysuria, or suprapubic tenderness *and* patient has a positive urine culture, that is, $\geq 10^5$ microorganisms per cm^3 of urine with no more than two species of microorganisms.

Criterion 2: Patient has at least *two* of the following signs or symptoms with no other recognized cause: fever ($>38^{\circ}\text{C}$), urgency, frequency, dysuria, or suprapubic tenderness *and* at least *one* of the following:

- positive dipstick for leukocyte esterase and/or nitrate
- pyuria (urine specimen with ≥ 10 wbc/ mm^3 or ≥ 3 wbc/high power field of unspun urine)
- organisms seen on Gram stain of unspun urine
- at least *two* urine cultures with repeated isolation of the same

uropathogen (gram-negative bacteria or *S. saprophyticus*) with $\geq 10^2$ colonies/ml in nonvoided specimens

- $\leq 10^5$ colonies/ml of a single uropathogen (gram-negative bacteria or *S. saprophyticus*) in a patient being treated with an effective antimicrobial agent for a urinary tract infection
- physician diagnosis of a urinary tract infection
- physician institutes appropriate therapy for a urinary tract infection.

Criterion 3: Patient ≤ 1 year of age has at least *one* of the following signs or symptoms with no other recognized cause: fever ($>38^{\circ}\text{C}$), hypothermia ($<37^{\circ}\text{C}$), apnea, bradycardia, dysuria, lethargy, or vomiting *and* patient has a positive urine culture, that is, $\geq 10^5$ microorganisms per cm^3 of urine with no more than two species of microorganisms.

Criterion 4: Patient ≤ 1 year of age has at least *one* of the following signs or symptoms with no other recognized cause: fever ($>38^{\circ}\text{C}$), hypothermia ($<37^{\circ}\text{C}$), apnea, bradycardia, dysuria, lethargy, or vomiting *and* at least *one* of the following:

- positive dipstick for leukocyte esterase and/or nitrate
- pyuria (urine specimen with ≥ 10

wbc/ mm^3 or >3 wbc/high power field of unspun urine)

- organisms seen on gram stain or unspun urine
- at least *two* urine cultures with repeated isolation of the same uropathogen (gram-negative bacteria or *S. saprophyticus*) with $\geq 10^2$ colonies/ml in nonvoided specimens
- $\leq 10^5$ colonies/ml of a single uropathogen (gram-negative bacteria or *S. saprophyticus*) in a patient being treated with an effective antimicrobial agent for a urinary tract infection
- physician diagnosis of a urinary tract infection
- physician institutes appropriate therapy for a urinary tract infection.

COMMENTS:

- A positive culture of a urinary catheter tip is *not* an acceptable laboratory test to diagnose a urinary tract infection.
- Urine cultures must be obtained using appropriate technique, such as clean catch collection or catheterization.
- In infants, a urine culture should be obtained by bladder catheterization or suprapubic aspiration; a positive urine culture from a bag specimen is unreliable and should be confirmed by a specimen aseptically obtained by catheterization or suprapubic aspiration.

Bloodstream infection with clinical signs and growth of same skin contaminant from two separate blood samples

- Patient has at least one of the following signs or symptoms: fever ($>38^{\circ}\text{C}.$), chills, or hypotension and 2 positive blood cultures for a common skin contaminant (from 2 separate blood samples drawn within 48 hours).

skin contaminants = coagulase-negative staphylococci, *Micrococcus sp.*, *Propionibacterium acnes*, *Bacillus sp.*, *Corynebacterium sp.*



BSI-A2


1
⇐

clinical_signs_of_BSI (t-1d, t, t+1d)

^

same_skin_contaminant_from_two_separate_blood_samples



Decomposition—clinical signs



Clinical signs—fever

fever (t-1d) $\Leftarrow$...

fever (t) $\Leftarrow$




data import
intensive care unit
[maximum value
of the day
e.g., 38.5 °C]

fever (t+1d) $\Leftarrow$...

← ↑ → ⇨

Processing layers



Cockpit surveillance at the infection control unit: Three criteria-based definitions in two patients are completely fulfilled (100%), backtracking of the logical chain of reasoning is provided ...

Moni IV

Verwaltung Abmelden

Inferenz Surveillance Export Themes Hilfe

von 1980-08-25 bis 2008-08-25 Anzeigen

Stationen/Patienten

13H1

13C1

13C2

13B3

13C3

13B1

BSI-A 1, PN4 1 T1

BSI-A 2 T2

13H3

13H2

BSI-A 1, PN4 1 T1

2000-01-01

Messwerte

Interpretationen und Diagnosen

BSI-A (primäre Sepsis) 100 %

2000-01-08

Messwerte

beatmet 100 %

Interpretationen und Diagnosen

PN4 100 %

PN4 (beatmet) 100 %

PN5 100 %

Fieber 100 %

klinische Anzeichen für Pneumonie (beatmet) 100 %

wiederholter radiolog. Hinweis auf Pneumonie 100 %

BSI-A (primäre Sepsis)

pos. Blutkultur 100 %

... down to the level of detailed clinical and laboratory findings

Moni IV

Verwaltung Abmelden

Inferenz Surveillance Export Themes Hilfe

von 1980-08-25 bis 2008-08-25

Anzeigen

BSI-A (primäre Sepsis)

Regel: BSI-A.1 (Regelgewicht: 100 %)

Parameter	Wert	Station	ermittelt	Urheber	Anmerkung
BSI-A (primäre Sepsis)	1.0	1381	Aug 25, 2008 10:34:22 AM	[mxt]	

Bedingungen

Parameter	Wert	Station	ermittelt	Urheber	Anmerkung
pos. BlutKultur	100 %	1381		mibi. Import	none; Blut; E. Coli. 10 ⁶ KBE/ml

BSI-A (primäre Sepsis) trifft zu, wenn ein kultureller Nachweis von pathogenen Erregern im Blut vorliegt, die nicht in anderem Material zu finden sind.


Arden and Health Level Seven (HL7)

- A standard language for writing situation-action rules that can trigger alerts based on abnormal clinical events detected by a clinical information system.

van Bommel, J.H., Musen, M.A. (eds.) (1997)
Handbook of Medical Informatics, Springer-Verlag,
Heidelberg, Glossary, p. 559.

- Each module, referred to as a Medical Logic Module (MLM), contains sufficient knowledge to make a single decision.
extended by packages of MLMs for complex clinical decision support
 - Contraindication alerts, management suggestions, data interpretations, treatment protocols, and diagnosis scores are examples of the health knowledge that can be represented using MLMs.
extended by single and differential diagnosis, temporal monitoring, control systems, selective computerized processing of clinical pathways and management guidelines
 - The first version of the ARDEN syntax was administered and issued by the American Society for Testing and Materials ASTM (1992, version 1.0; today 2.5). Since 1998, an Arden Syntax Special Interest Group (SIG) is part of the HL7 organization (www.hl7.org).
-

Arden, ArdenServer, and health care information systems



Significance of nosocomial infections

- 3 to 14% of patients admitted to acute care hospitals acquire one or more nosocomial infections
- in consequence, 5 to 7% of them die

Vienna General Hospital with 2,200 beds:

patients admitted to wards: 94,715

days of care: 688,619


average length of stay: 6.1 days

costs / patient / day: EUR 678.-

- nosocomial infections: 4,262 patients / year (rate of 4.5% assumed)
- 213 out of them die / year (5% mortality assumed)
- additional costs of **EUR 14,448,180.-** (5 days of prolonged stay, in average)

source: Prof. Dr. med. Ojan Assadian, Division of Hospital Hygiene, Medical University of Vienna (2002)

Cooperating computational intelligence in medicine—as a safety net for health care processes



Towards a science of clinical medicine

patient's medical data
and
healthcare processes
for
human processing

≠

patient's medical data
and
healthcare processes
for
machine processing

observations
e.g., temperature chart
skin color (jaundice, livid, ...)
...

measurements
e.g., CRP
color measurement
...

“Measure what is measurable, and make measurable what is not so.”

Galileo Galilei
1564–1642

Crucial point in clinical medicine:

“Digitize what is digitizable, and make digitizable what is not so.”

Klaus-Peter Adlassnig